Biologics
FDA to Miss Savara’s User Fee Date as BLA Review Continues
FDA will not meet its 11/22 user fee action date for Savara’s BLA seeking approval of molgramostim inhalation solution for treating autoimmune pulmonary alveolar proteinosis (aPAP), according to the company. The agency’s review is continuing, and no revised action date has been provided. Molgramostim is an investigational